U.S., Feb. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07433335) titled 'A Study to Assess the Safety and Tolerabiliy of SR-878 in Patients With Rheumatoid Arthritis' on Feb. 17.
Brief Summary: SR-878 is a newly developed medicine that aims to treat autoimmune disorders. It inhibits a protein (iRhom2), that regulates enzymes that are involved in the production of cytokines (small proteins that are crucial in controlling the activity of immune system cells). The aim of this clinical trial is to find a suitable safe and effective SR-878 dose for patients with rheumatoid arthritis. The study will include a screening period, an inpatient treatment period, and an outpatient follow-up period. The study duratio...